About: Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19
Creator	Wang, Jun Zhu, Chengliang Feng, Fan Feng, F Feng, J Feng, Jia Jia, ( Jia, Qingzhu Qiu, Y Qiu, Yanru Song, Qibin Zhang, Zhang, Bicheng Zhou, Xiaoyang Zhu, Bo
Source	MedRxiv
abstract	Background: A recently emerging respiratory disease named coronavirus disease 2019 (COVID-19) has quickly spread across the world. This disease is initiated by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and uncontrolled cytokine storm, but it remains unknown as to whether a robust antibody response is related to clinical deterioration and poor outcome in laboratory-confirmed COVID-19 patients. Methods: Anti-SARS-CoV-2 IgG and IgM antibodies were determined by chemiluminescence analysis (CLIA) in COVID-19 patients from a single center in Wuhan. Median IgG and IgM levels in acute and convalescent-phase sera (within 35 days) for all included patients were calculated and compared among severe and nonsevere patients. Immune response phenotyping based on late IgG levels and neutrophil-to-lymphocyte ratio (NLR) was characterized to stratify patients with different disease severities and outcome. Laboratory parameters in patients with different immune response phenotypes and disease severities were analyzed. Findings: A total of 222 patients were included in this study. IgG was first detected on day 4 of illness, and its peak levels occurred in the fourth week. Severe cases were more frequently found in patients with high IgG levels, compared to those who with low IgG levels (51.8% versus 32.3%; p=0.008). Severity rates for patients with NLRhiIgGhi, NLRhiIgGlo, NLRloIgGhi, and NLRloIgGlo phenotype was 72.3%, 48.5%, 33.3%, and 15.6%, respectively (p<0.0001). Furthermore, severe patients with NLRhiIgGhi, NLRhiIgGlo had higher proinflammatory cytokines levels including IL-2, IL-6 and IL-10, and decreased CD4+ T cell count compared to those with NLRloIgGlo phenotype (p<0.05). Recovery rate for severe patients with NLRhiIgGhi, NLRhiIgGlo, NLRloIgGhi, and NLRloIgGlo phenotype was 58.8% (20/34), 68.8% (11/16), 80.0% (4/5), and 100% (12/12), respectively (p=0.0592). Dead cases only occurred in NLRhiIgGhi and NLRhiIgGlo phenotypes. Interpretation: COVID-19 severity is associated with increased IgG response, and an immune response phenotyping based on late IgG response and NLR could act as a simple complementary tool to discriminate between severe and nonsevere COVID-19 patients, and further predict their clinical outcome.
has issue date	2020-03-16(xsd:dateTime)
bibo:doi	10.1101/2020.03.12.20035048
has license	medrxiv
sha1sum (hex)	778d1abeb8f189d090a447ee27e7ab5b7836a34e
schema:url	https://doi.org/10.1101/2020.03.12.20035048
resource representing a document's title	Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19
resource representing a document's body	covid:778d1abeb8f189d090a447ee27e7ab5b7836a34e#body_text
is schema:about of	named entity 'Immune' named entity 'HOST IMMUNE RESPONSE' named entity 'FOCUSING' named entity 'ACQUIRED IMMUNITY' named entity 'DATABASES' named entity 'IDENTIFIED' named entity 'INFRASTRUCTURE' named entity 'VIRAL LOAD' named entity 'SARS-CoV-2' named entity 'viral load' named entity 'immune response' named entity 'infection' named entity 'pathogenesis' named entity 'organ' named entity 'lymphocyte' named entity 'virus' named entity 'peer review' named entity 'innate immunity' named entity 'Research Ethics' named entity 'IL-10' named entity 'antibody' named entity 'IgG' named entity 'intensive care unit' named entity 'TNF-α' named entity 'NLR' named entity 'NLR' named entity 'peer review' named entity 'phenotype' named entity 'COVID' named entity 'IgG' named entity 'Serum samples' named entity 'CD4+ T cell' named entity 'IL-6' named entity 'COVID' named entity 'IgG' named entity 'IgG' named entity 'IL-6' named entity 'epidemiological' named entity 'coronavirus disease 2019' named entity 'epidemiological' named entity 'CD4+ T cell' named entity 'tumor necrosis factor-α' named entity 'NLR' named entity 'NLR' named entity 'IgG' named entity 'secondary antibody' named entity 'COVID' named entity 'immune response' named entity 'Shanghai' named entity 'IgG' named entity 'IL-6' named entity 'serological' named entity 'NLR' named entity 'IgM' named entity 'NLR' named entity 'IFN-γ' named entity 'acquired immunity' named entity 'phenotype' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'treatment of patients' named entity 'March 16, 2020' named entity 'tissue damage' named entity 'cytokine' named entity 'NLR' named entity 'SARS-CoV-2' named entity 'phenotypes' named entity 'NLR' named entity 'lymphocyte' named entity 'IgM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software